Metraipolis › archive › dc_f47a600d7c8a

Immunogenicity assessment for vidutolimod: a risk-driven approach for a simplified 1-tiered, singlicate anti-drug antibody testing strategy — Europe PMC PMID:42238586

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/42238586
DOI: 10.3389/fimmu.2026.1751717
License (as archived): solo-consultazione
Archived: 2026-11-01T14:28:44.358Z
SHA-256 of the archived text: 35785c4636661ee680c9a2b7a1cff1d4648bb8ffd83d1007b69b432cd223738c
Stable URL of this page: https://metraipolis.com/documento/dc_f47a600d7c8a

How to cite

Immunogenicity assessment for vidutolimod: a risk-driven approach for a simplified 1-tiered, singlicate anti-drug antibody testing strategy — Europe PMC PMID:42238586 — Europe PMC (en), https://europepmc.org/article/MED/42238586 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_f47a600d7c8a (Metraipolis archive dc_f47a600d7c8a, sha256 35785c4636661ee680c9a2b7a1cff1d4648bb8ffd83d1007b69b432cd223738c)

BibTeX

@misc{dcf47a600d7c8a,
  title = {Immunogenicity assessment for vidutolimod: a risk-driven approach for a simplified 1-tiered, singlicate anti-drug antibody testing strategy — Europe PMC PMID:42238586},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42238586},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_f47a600d7c8a; sha256 35785c4636661ee680c9a2b7a1cff1d4648bb8ffd83d1007b69b432cd223738c},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42238586. Agents can read the archived copy with the MCP tool read_document.